RodrigoOtavio BoffMaegawaMD

PubMed

• 2 citations
  Molecular response in newly diagnosed chronic-phase chronic myeloid leukemia: prediction modeling and pathway analysis.
  Jerald P Radich, Matthew Wall, Susan Branford, Catarina D Campbell, Shalini Chaturvedi, Daniel J DeAngelo, Michael Deininger, Justin Guinney, Andreas Hochhaus, Timothy...> ;Haematologica. 2023 Jun 1
• Therapy for patients with chronic phase-chronic myeloid leukemia previously treated with ⩾2 tyrosine kinase inhibitors: a systematic literature review.
  Ehab Atallah, Lovneet Saini, Rodrigo Maegawa, Tanvi Rajput, Regina Corbin, Ricardo Viana> ;Therapeutic Advances in Hematology. 2023 Jan 1
• 48 citations
  A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation.
  Matthew S. Davids, Haesook T. Kim, Caitlin Costello, Alex F. Herrera, Frederick L. Locke, Rodrigo O. Maegawa, Alexandra Savell, Michael Mazzeo, Adrienne Anderson, Alex...> ;Blood. 2020 Jun 11
• 30 citations
  Reduced intensity allogeneic hematopoietic stem cell transplantation for MDS using tacrolimus/sirolimus-based GVHD prophylaxis
  Ryotaro Nakamura, Joycelynne Palmer, Margaret R. O'Donnell, Tracey Stiller, Sandra H. Thomas, Joseph Chao, Joseph C. Alvarnas, Pablo M. Parker, Vinod Pullarkat, Rodrig...> ;Leukemia Research. 2012 Sep 1
• 11 citations
  Triple-Negative Breast Cancer: Unique Biology and Its Management
  Rodrigo O.B. Maegawa, Shou Ching Tang> ;Cancer Investigation. 2010 Sep 14
• 7 citations
  Angioimmunoblastic T-cell lymphoma with an evolving Epstein Barr virus-positive diffuse large B-cell lymphoma with unusual clinical and pathologic findings.
  Rodrigo O. B. Maegawa, Sajid Hussain, Daniel C. Danila, Julie Teruya-Feldstein, Robert G. Maki, Owen A. O'Connor> ;Leukemia & Lymphoma. 2007 Oct 1
• 39 citations
  Four new mutations in the BCHE gene of human butyrylcholinesterase in a Brazilian blood donor sample.
  Ricardo L.R. Souza, Liya R. Mikami, Rodrigo O.B. Maegawa, Eleidi A. Chautard-Freire-Maia> ;Molecular Genetics and Metabolism. 2005 Apr 1
• Join now to see all

Lectures

• Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• A Phase II Study of the Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone (RVD) Combination Therapy for Patients with Newly Diagnosed Mult... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018